Clinical Research Directory
Browse clinical research sites, groups, and studies.
Second-line Treatment of Primary Autoimmune Hemolytic Anemia
Sponsor: Assiut University
Summary
the cyclosporine showed efficacy in many immune cytopenic diseases in the light of numerous case reports and retrospective data. This study compares cyclosporin versus rituximab in steroid-refractory anemia.
Official title: Cyclosporine As a Second-line Treatment of Primary Autoimmune Hemolytic Anemia
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2021-10-20
Completion Date
2026-11-30
Last Updated
2025-03-20
Healthy Volunteers
No
Conditions
Interventions
Cyclosporine
2.5-5 mg orally for 3 months
Rituximab
375 mg/ m2 weekly dose for a maximum of 4 weeks
Locations (2)
Assiut university hospital
Asyut, Asyut Governorate, Egypt
Assiut university hospital
Asyut, Asyut Governorate, Egypt